1. Home
  2. LGCY vs ALEC Comparison

LGCY vs ALEC Comparison

Compare LGCY & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCY
  • ALEC
  • Stock Information
  • Founded
  • LGCY 2009
  • ALEC 2013
  • Country
  • LGCY United States
  • ALEC United States
  • Employees
  • LGCY N/A
  • ALEC N/A
  • Industry
  • LGCY
  • ALEC Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LGCY
  • ALEC Health Care
  • Exchange
  • LGCY NYSE
  • ALEC Nasdaq
  • Market Cap
  • LGCY 117.7M
  • ALEC 124.0M
  • IPO Year
  • LGCY 2024
  • ALEC 2019
  • Fundamental
  • Price
  • LGCY $11.05
  • ALEC $1.76
  • Analyst Decision
  • LGCY Strong Buy
  • ALEC Buy
  • Analyst Count
  • LGCY 2
  • ALEC 8
  • Target Price
  • LGCY $10.65
  • ALEC $4.50
  • AVG Volume (30 Days)
  • LGCY 97.1K
  • ALEC 431.4K
  • Earning Date
  • LGCY 05-15-2025
  • ALEC 08-11-2025
  • Dividend Yield
  • LGCY N/A
  • ALEC N/A
  • EPS Growth
  • LGCY 21.53
  • ALEC N/A
  • EPS
  • LGCY 0.62
  • ALEC N/A
  • Revenue
  • LGCY $58,970,210.00
  • ALEC $88,339,000.00
  • Revenue This Year
  • LGCY $33.77
  • ALEC N/A
  • Revenue Next Year
  • LGCY $24.88
  • ALEC $319.82
  • P/E Ratio
  • LGCY $17.76
  • ALEC N/A
  • Revenue Growth
  • LGCY 37.92
  • ALEC N/A
  • 52 Week Low
  • LGCY $3.60
  • ALEC $0.87
  • 52 Week High
  • LGCY $12.30
  • ALEC $6.61
  • Technical
  • Relative Strength Index (RSI)
  • LGCY N/A
  • ALEC 60.62
  • Support Level
  • LGCY N/A
  • ALEC $1.74
  • Resistance Level
  • LGCY N/A
  • ALEC $1.70
  • Average True Range (ATR)
  • LGCY 0.00
  • ALEC 0.12
  • MACD
  • LGCY 0.00
  • ALEC 0.01
  • Stochastic Oscillator
  • LGCY 0.00
  • ALEC 51.09

About LGCY LEGACY EDUCATION INC

Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.

About ALEC Alector Inc.

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Share on Social Networks: